AU2012311979A1 - MRM/SRM assay for Death Receptor 5 protein - Google Patents

Abstract

Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring / Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the DR5 protein are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the DR5 protein. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of a DR5 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence

Description

WO 2013/044261 PCT/US2012/056961 MRM/SRM Assay for Death Receptor 5 Protein This application claims the benefit of U.S. Provisional Application No. 61/538,096, filed September 22, 2011, entitled "MRM/SRM Assay for Death Receptor 5 Protein," the content of which are hereby incorporated by referenced in their entirety. 5 Introduction Specific peptides derived from subsequences of the Death Receptor 5 (DR5) protein are provided. The peptide sequences and fragmentation/transition ions for each peptide are particularly useful in a mass spectrometry-based Selected Reaction Monitoring (SRM) assay, which can also be referred to as a Multiple Reaction Monitoring (MRM) assay. Such assays are 10 referred to herein as SRM/MRM. The use of peptides for quantitative SRM/MRM analysis of the DR5 proteins is described. This SRM/MRM assay can be used to measure relative or absolute quantitative levels of one or more of the specific peptides from the DR5 protein. This provides a means of measuring the amount of the DR5 protein in a given protein preparation obtained from a biological sample 15 by mass spectrometry. More specifically, the SRM/MRM assay can measure these peptides directly in complex protein lysate samples prepared from cells procured from patient tissue samples, such as formalin fixed cancer patient tissue. Methods of preparing protein samples from formalin-fixed tissue are described in U.S. Patent No. 7,473,532, the contents of which are hereby incorporated 20 by reference in their entirety. The methods described in U.S. Patent No. 7,473,532 may conveniently be carried out using Liquid TissueTM reagents and protocol available from OncoPlexDx (formerly Expression Pathology Inc., Rockville, MD). Results from the SRM/MRM assay, where the proteins are analyzed individually or simultaneously, can be used to correlate accurate and precise quantitative amounts of these 25 proteins within specific tissue samples (e.g., cancer tissue sample) of the patient or subject from whom the tissue (biological sample) was collected and preserved. This not only provides diagnostic information about the cancer, but also permits a physician or other medical professional to determine appropriate therapy for the cancer patient. Such an assay that provides diagnostically and therapeutically important information about levels of protein expression in a 30 diseased tissue or other patient sample is termed a "companion diagnostic" assay. For example, such an assay can be designed to diagnose the stage or degree of a cancer and determine a therapeutic agent to which a patient is most likely to respond. 1 WO 2013/044261 PCT/US2012/056961 Summary The assays described herein measure relative or absolute levels of specific unmodified peptides from the DR5 protein and also can measure absolute or relative levels of specific modified peptides from the DR5 protein. Examples of modifications include phosphorylated 5 amino acid residues (e.g. phosphotyrosine, phosphoserine and phosphothreonine) and glycosylated amino acid residues (e.g. glycosylated asparagine residues) that are present on the peptides. Relative quantitative levels of the DR5 protein are determined by the SRM/MRM methodology, for example, by comparing SRM/MRM signature peak areas (e.g., signature peak 10 area or integrated fragment ion intensity) of an individual DR5 peptide in different samples. Alternatively, it is possible to compare multiple SRM/MRM signature peak areas for multiple DR5 signature peptides, where each peptide has its own specific SRM/MRM signature peak, to determine the relative DR5 protein content in one biological sample with the DR5 protein content in one or more additional or different biological samples. In this way, the amount of a 15 particular peptide, or peptides, from the DR5 protein, and therefore the amount of the DR5 protein, is determined relative to the same DR5 peptide, or peptides, across 2 or more biological samples under the same experimental conditions. In addition, relative quantitation can be determined for a given peptide, or peptides, from the DR5 protein within a single sample by comparing the signature peak area for that peptide by SRM/MRM methodology to the signature 20 peak area for another and different peptide, or peptides, from a different protein, or proteins, within the same protein preparation from the biological sample. In this way, the amount of a particular peptide from the DR5 protein, and therefore the amount of the DR5 protein, is determined relative one to another within the same sample. These approaches generate quantitation of an individual peptide, or peptides, from the DR5 protein to the amount of another 25 peptide, or peptides, between samples and within samples wherein the amounts as determined by peak area are relative one to another, regardless of the absolute weight to volume or weight to weight amounts of the DR5 peptide in the protein preparation from the biological sample. Relative quantitative data about individual signature peak areas between different samples are normalized to the amount of protein analyzed per sample. Relative quantitation can be 30 performed across many peptides from multiple proteins and the DR5 protein simultaneously in a single sample and/or across many samples to gain insight into relative protein amounts, one peptide/protein with respect to other peptides/proteins. Absolute quantitative levels of the DR5 protein are determined by, for example, the SRM/MRM methodology whereby the SRM/MRM signature peak area of an individual peptide 2 WO 2013/044261 PCT/US2012/056961 from the DR5 protein in one biological sample is compared to the SRM/MRM signature peak area of an exogenously added "spiked" internal standard. In one embodiment, the internal standard is a synthetic version of the same exact DR5 peptide that contains one or more amino acid residues labeled with one or more heavy isotopes. Suitable isotope-labeled internal 5 standards are synthesized so that, when analyzed by mass spectrometry, each standard generates a predictable and consistent SRM/MRM signature peak that is different and distinct from the native DR5 peptide signature peak and which can be used as a comparator peak. Thus, when the internal standard is spiked in a known amount into a protein preparation from a biological sample and analyzed by mass spectrometry, the SRM/MRM signature peak area of the native 10 peptide from the sample can be compared to the SRM/MRM signature peak area of the internal standard peptide. This numerical comparison provides either the absolute molarity and/or absolute weight of the native peptide present in the original protein preparation from the biological sample. Absolute quantitative data for fragment peptides are displayed according to the amount of protein analyzed per sample. Absolute quantitation can be performed across many 15 peptides, and thus proteins, simultaneously in a single sample and/or across many samples to gain insight into absolute protein amounts in individual biological samples and in entire cohorts of individual samples. The SRM/MRM assay method can be used to aid diagnosis of the stage of cancer, for example, directly in patient-derived tissue, such as formalin fixed tissue, and to aid in 20 determining which therapeutic agent would be most advantageous for use in treating that patient. Cancer tissue that is removed from a patient either through surgery, such as for therapeutic removal of partial or entire tumors, or through biopsy procedures conducted to determine the presence or absence of suspected disease, is analyzed to determine whether or not a specific protein, or proteins, and which forms of proteins, are present in that patient tissue. Moreover, the 25 expression level of a protein, or multiple proteins, can be determined and compared to a "normal" or reference level found in healthy tissue. Normal or reference levels of proteins found in healthy tissue may be derived from, for example, the relevant tissues of one or more individuals that do not have cancer. Alternatively, normal or reference levels may be obtained for individuals with cancer by analysis of relevant tissues not affected by the cancer. 30 Alternatively, normal or reference levels may be obtained for individuals with cancer by analysis of relevant tissues not affected by the cancer. Assays of protein levels (e.g., DR5 levels) can also be used to diagnose the stage of cancer in a patient or subject diagnosed with cancer by employing the DR5 levels. Levels of an individual DR5 peptide is defined as molar amount of the peptide determined by the SRM/MRM assay per total amount of protein lysate analyzed. 35 Information regarding DR5 can thus be used to aid in determining stage or grade of a cancer by 3 WO 2013/044261 PCT/US2012/056961 correlating the level of the DR5 protein (or fragment peptides of the DR5 protein) with levels observed in normal tissues. Assays of protein levels (e.g., DR5 levels) can also be used to diagnose the stage of cancer in a patient or subject diagnosed with cancer by employing the DR5 levels. Levels or 5 amounts of proteins or peptides can be defined as the quantity expressed in moles, mass or weight of a protein or peptide determined by the SRM/MRM assay. The level or amount may be normalized to total the level or amount of protein or another component in the lysate analyzed (e.g., expressed in micromoles/microgram of protein or micrograms /microgram of protein). In addition, the level or amount of a protein or peptide may be determined on volume basis, 10 expressed, for example, in micromolar or nanograms/microliter. The level or amount of protein or peptide as determined by the SRM/MRM assay can also be normalized to the number of cells analyzed. Information regarding DR5 can thus be used to aid in determining stage or grade of a cancer by correlating the level of the DR5 protein (or fragment peptides of the DR5 protein) with levels observed in normal tissues. 15 Once the stage and/or grade, and/or DR5 protein expression characteristics of the cancer has been determined, that information can be matched to a list of therapeutic agents (chemical and biological) developed to specifically treat cancer tissue that is characterized by, for example, abnormal expression of the protein or protein(s) (e.g., DR5) that were assayed. Matching information from an DR5 protein assay to a list of therapeutic agents that specifically targets, for 20 example, the DR5 protein or cells/tissue expressing the protein, defines what has been termed a personalized medicine approach to treating disease. The assay methods described herein form the foundation of a personalized medicine approach by using analysis of proteins from the patient's own tissue as a source for diagnostic and treatment decisions. The DR5 protein can be analyzed individually or in combination with other proteins in a personalized medicine approach 25 to diagnosing and treating cancer. These and other aspects of the present disclosure will become apparent to the skilled person in view of the description set forth below. Detailed Description 30 The Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) assay can be used to measure relative or absolute quantitative levels of one or more of the specific peptides from the DR5 protein, individually, in combinations, or simultaneously, and therefore provide a means of measuring the amount of the DR5 protein in a given protein preparation obtained from a biological sample by mass spectrometry. 4 WO 2013/044261 PCT/US2012/056961 More specifically, the SRM/MRM assay can measure these peptides directly in complex protein lysate samples prepared from cells procured from patient tissue samples, such as formalin fixed cancer patient tissue. Methods of preparing protein samples from formalin fixed tissue are described in U.S. Patent No. 7,473,532, the contents of which are hereby incorporated 5 by references in their entireties. The methods described in U.S. Patent No. 7,473,532 may conveniently be carried out using Liquid TissueTM reagents and protocol available from OncoPlexDx (formerly Expression Pathology Inc., Rockville, MD). The most widely and advantageously available form of tissues from cancer patient tissue is formalin fixed, paraffin embedded tissue. Formaldehyde/formalin fixation of surgically 10 removed tissue is by far and away the most common method of preserving cancer tissue samples worldwide and is the accepted convention for standard pathology practice. Aqueous solutions of formaldehyde are referred to as formalin. "100%" formalin consists of a saturated solution of formaldehyde (this is about 40% by volume or 37% by mass) in water, with a small amount of stabilizer, usually methanol to limit oxidation and degree of polymerization. The most common 15 way in which tissue is preserved is to soak whole tissue for extended periods of time (8 hours to 48 hours) in aqueous formaldehyde, commonly termed 10% neutral buffered formalin, followed by embedding the fixed whole tissue in paraffin wax for long term storage at room temperature. Thus molecular analytical methods to analyze formalin fixed cancer tissue will be the most accepted and heavily utilized methods for analysis of cancer patient tissue. 20 In principle, any predicted peptide derived from the DR5 protein, prepared for example by digesting with a protease of known specificity (e.g. trypsin), can be used as a surrogate reporter to determine the abundance of DR5 protein in a sample using a mass spectrometry based SRM/MRM assay. Similarly, any predicted peptide sequence containing an amino acid residue at a site that is known to be potentially modified in the DR5 protein also might 25 potentially be used to assay the extent of modification of the DR5 protein in a sample. According to one embodiment, DR5 fragment peptides may be generated in a variety of ways including using the Liquid TissueTM protocol described in US Patent 7,473,532. The Liquid TissueTM protocol and reagents produce peptide samples suitable for mass spectroscopic analysis from formalin fixed paraffin embedded tissue by proteolytic digestion of the proteins in 30 the tissue/biological sample. Suitable reagents and protocols also are commercially available from OncoPlexDx (formerly Expression Pathology Inc., Rockville, MD). In the Liquid TissueTM protocol the tissue/biological sample is heated in a buffer for an extended period of time (e.g., from about 800 C to about 1000 C for a period of time from about 10 minutes to about 4 hours) to reverse or release protein cross-linking. The buffer employed is 5 WO 2013/044261 PCT/US2012/056961 a neutral buffer, (e.g., a Tris-based buffer, or a buffer containing a detergent). Following heat treatment the tissue/biological sample is treated with one or more proteases including, but not limited to, trypsin, chymotrypsin, pepsin, and endoproteinase Lys-C for a time sufficient to disrupt the tissue and cellular structure of said biological sample and to liquefy the sample. 5 Exemplary conditions for the protease treatment are from 30 minutes to 24 hours at a temperature from 370 C to 65 C). Advantageously, endoproteases, and particularly combinations of two or three endoproteases, used either simultaneously or sequentially, are employed to liquefy the sample. For example, suitable combinations of proteases can include, but are not limited to, combinations of trypsin, endoproteinase Lys-C and chemotrypsin, such as 10 trypsin and endoproteinase Lys-C. The result of the heating and proteolysis is a liquid, soluble, dilutable biomolecule lysate. Advantageously, this liquid lysate is free of solid or particulate matter that can be separated from the lysate by centrifugation. Surprisingly, it was found that many potential peptide sequences from the DR5 protein are unsuitable or ineffective for use in mass spectrometry-based SRM/MRM assays for reasons 15 that are not immediately evident. As it was not possible to predict the most suitable peptides for MRM/SRM assay, it was necessary to experimentally identify modified and unmodified peptides in actual Liquid TissueTM lysates to develop a reliable and accurate SRM/MRM assay for the DR5 protein. While not wishing to be bound by any theory, it is believed that some peptides might, for example, be difficult to detect by mass spectrometry because they do not ionize well 20 or produce fragments that are not distinct from those generated from other proteins. Peptides may also fail to resolve well in separation (e.g., liquid chromatography), or may adhere to glass or plastic ware, which leads to erroneous results in the SRM/MRM assay.. DR5 peptides found in various embodiments of this disclosure (for example, Tables 1 and 2 below) were derived from the DR5 protein by protease digestion of all the proteins within 25 a complex Liquid TissueTM lysate prepared from cells procured from formalin fixed cancer tissue. Unless noted otherwise, in each instance the protease was trypsin. The Liquid TissueTM lysate was then analyzed by mass spectrometry to determine those peptides derived from the DR5 protein that are detected and analyzed by mass spectrometry. Identification of a specific preferred subset of peptides for mass-spectrometric analysis is based on: 1) experimental 30 determination of which peptide or peptides from a protein ionize in mass spectrometry analyses of Liquid TissueTM lysates, and 2) the ability of the peptide to survive the protocol and experimental conditions used in preparing a Liquid TissueTM lysate. This latter property extends not only to the amino acid sequence of the peptide but also to the ability of a modified amino acid residue within a peptide to survive in modified form during the sample preparation. 6 WO 2013/044261 PCT/US2012/056961 Protein lysates from cells procured directly from formalin (formaldehyde) fixed tissue were prepared using the Liquid TissueTM reagents and protocol. This entails collecting cells into a sample tube via tissue microdissection followed by heating the cells in the Liquid TissueTM buffer for an extended period of time. Once the formalin-induced cross linking has been 5 negatively affected, the tissue/cells are then digested to completion in a predictable manner using a protease such as, trypsin. The skilled artisan will recognize that other proteases, and in particular, endoproteases may be used in place of, or in addition to, trypsin. Each protein lysate was used to prepare a collection of peptides by digestion of intact polypeptides with the protease or protease combination. Each Liquid TissueTM lysate was analyzed (e.g., by ion trap mass 10 spectrometry) to perform multiple global proteomic surveys of the peptides where the data was presented as identification of as many peptides as could be identified by mass spectrometry from all cellular proteins present in each protein lysate. An ion trap mass spectrometer or another form of a mass spectrometer that is capable of performing global profiling for identification of as many peptides as possible from a single complex protein/peptide lysate may be employed. Ion 15 trap mass spectrometers may, however, be the best type of mass spectrometer for conducting global profiling of peptides. Although SRM/MRM assays can be developed and performed on any type of mass spectrometer, including a MALDI, ion trap, or triple quadrupole, an instrument platform for SRM/MRM assay is often considered to be a triple quadrupole instrument platform. Once as many peptides as possible were identified in a single mass spectrometric analysis 20 of a single lysate under the conditions employed, then the list of identified peptides was collated and used to determine the proteins that were detected in that lysate. This process was repeated for multiple Liquid TissueTM lysates, and the very large list of peptides was collated into a single dataset. The resulting dataset represents the peptides that can be detected in the type of biological sample that was analyzed (after protease digestion), and specifically in a Liquid 25 TissueTM lysate of the biological sample, and thus includes the peptides for specific proteins, such as for example the DR5 protein. In one embodiment, the DR5 tryptic peptides identified as useful in the determination of absolute or relative amounts of the DR5 protein include one or more, two or more, or three of the peptides of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, each of which are shown in Table 30 1. Each of those peptides was detected by mass spectrometry in Liquid TissueTM lysates prepared from formalin fixed, paraffin embedded tissue. Thus, each of the peptides in Table 1, or any combination of those peptides (e.g., one or more, two or more, or three of those peptides recited in Table 1) are candidates for use in quantitative SRM/MRM assay for the DR5 protein in human biological samples, including directly in formalin fixed patient tissue. Table 2 shows 35 additional information regarding the peptides shown in Table 1. 7 WO 2013/044261 PCT/US2012/056961 Table 1 SEQ ID Peptide sequence SEQ ID NO: 1 LLVPANEGDPTETLR SEQ ID NO: 2 IEDHLLSSGK SEQ ID NO: 3 DASVHTLLDALETLGER Table 2 Mono Precursor Precursor Transition SEQ ID Peptide sequence IstpcMs hreSae mzmz Ion Type Isotopic Mass Charge State m/z m/z SEQ ID NO: 1 LLVPANEGDPTETLR 1623.847 2 812.931 716.393 y6 2 812.931 888.442 y8 2 812.931 1017.484 y9 2 812.931 1131.527 y10 2 812.931 1299.617 y12 SEQ ID NO: 2 IEDHLLSSGK 1097.572 2 549.793 491.282 y5 2 549.793 604.366 y6 2 549.793 741.425 y7 2 549.793 856.452 y8 SEQ ID NO: 3 DASVHTLLDALETLGER 1838.937 2 920.4749756 888.478 y8 2 920.4749756 1003.505 Y 9 2 920.4749756 1116.589 Y 10 5 2 920.4749756 1229.673 Y 11 The DR5 tryptic peptides listed in Table 1 include those detected from multiple Liquid TissueTM lysates of multiple different formalin fixed tissues of different human organs including prostate, colon, and breast. Each of those peptides is considered useful for quantitative 10 SRM/MRM assay of the DR5 protein in formalin fixed tissue. Further data analysis of these experiments indicated no preference is observed for any specific peptides from any specific organ site. Thus, each of these peptides is believed to be suitable for conducting SRM/MRM assays of the DR5 protein on a Liquid TissueTM lysate from any formalin fixed tissue originating from any biological sample or from any organ site in the body. 15 One consideration for conducting an SRM/MRM assay is the type of instrument that may be employed in the analysis of the peptides. Although SRM/MRM assays can be developed and performed on any type of mass spectrometer, including a MALDI, ion trap, or triple quadrupole, the most advantageous instrument platform for SRM/MRM assay is often considered to be a triple quadrupole instrument platform. That type of a mass spectrometer may be considered to 20 be the most suitable instrument for analyzing a single isolated target peptide within a very 8 WO 2013/044261 PCT/US2012/056961 complex protein lysate that may consist of hundreds of thousands to millions of individual peptides from all the proteins contained within a cell. In order to most efficiently implement an SRM/MRM assay for each peptide derived from the DR5 protein it is desirable to utilize information in addition to the peptide sequence in 5 the analysis. That additional information may be used in directing and instructing the mass spectrometer (e.g. a triple quadrupole mass spectrometer), to perform the correct and focused analysis of specific targeted peptide(s), such that the assay may be effectively performed. The additional information about target peptides in general, and about specific DR5 peptides, may include one or more of the mono isotopic mass of the peptide, its precursor charge 10 state, the precursor m/z value, the m/z transition ions, and the ion type of each transition ion. Additional peptide information that may be used to develop an SRM/MRM assay for the DR5 protein is shown in Table 2. The methods described below can be used to: 1) identify candidate peptides from the DR5 protein that can be used for a mass spectrometry-based SRM/MRM assay for the DR5 15 protein, 2) develop individual SRM/MRM assays, or multiplexed assays, for target peptides from the DR5 protein in order to correlate to cancer, and 3) apply quantitative DR5 assays to cancer diagnosis and/or choice of optimal therapy for cancer. Assay Methods 20 I. Identification of SRM/MRM candidate fragment peptides for the DR5 protein: a. Prepare a Liquid TissueTM protein lysate from a formalin fixed biological sample using a protease or proteases, (that may or may not include trypsin), to digest proteins b. Analyze all protein fragments in the Liquid TissueTM lysate on an ion trap tandem mass spectrometer and identify all fragment peptides from the DR5 protein, where 25 individual fragment peptides do not contain any peptide modifications such as phosphorylations or glycosylations c. Analyze all protein fragments in the Liquid TissueTM lysate on an ion trap tandem mass spectrometer and identify all fragment peptides from the DR5 protein that carry peptide modifications such as for example phosphorylated or glycosylated residues 30 d. All peptides generated by a specific digestion method from the entire, full length DR5 protein potentially can be measured, but preferred peptides used for development of the SRM/MRM assay are those that are identified by mass spectrometry directly in a 9 WO 2013/044261 PCT/US2012/056961 complex Liquid TissueTM protein lysate prepared from a formalin fixed biological sample e. Peptides that are specifically modified (phosphorylated, glycosylated, etc.) in patient tissue and which ionize, and thus detected, in a mass spectrometer when analyzing a 5 Liquid TissueTM lysate from a formalin fixed biological sample are identified as candidate peptides for assaying peptide modifications of the DR5 protein II. Mass Spectrometry Assay for Fragment Peptides from DR5 protein a. SRM/MRM assay on a triple quadrupole mass spectrometer for individual fragment peptides identified in a Liquid TissueTM lysate is applied to peptides from the DR5 10 protein i. Determine optimal retention time for a fragment peptide for optimal chromatography conditions including but not limited to gel electrophoresis, liquid chromatography, capillary electrophoresis, nano-reversed phase liquid chromatography, high performance liquid chromatography, or reverse phase 15 high performance liquid chromatography ii. Determine the mono isotopic mass of the peptide, the precursor charge state for each peptide, the precursor m/z value for each peptide, the m/z transition ions for each peptide, and the ion type of each transition ion for each fragment peptide in order to develop an SRM/MRM assay for each peptide. 20 iii. SRM/MRM assay can then be conducted using the information from (i) and (ii) on a triple quadrupole mass spectrometer where each peptide has a characteristic and unique SRM/MRM signature peak that precisely defines the unique SRM/MRM assay as performed on a triple quadrupole mass spectrometer 25 b. Perform SRM/MRM analysis so that the amount of the fragment peptide of the DR5 protein that is detected, as a function of the unique SRM/MRM signature peak area from an SRM/MRM mass spectrometry analysis, can indicate both the relative and absolute amount of the DR5 protein in a particular protein lysate. i. Relative quantitation may be achieved by: 30 1. Determining increased or decreased presence of the DR5 protein by comparing the SRM/MRM signature peak area from a given DR5 peptide detected in a Liquid TissueTM lysate from one formalin fixed biological sample to the same SRM/MRM signature peak area of the same DR5 fragment peptide in at least a second, third, fourth or more 10 WO 2013/044261 PCT/US2012/056961 Liquid TissueTM lysates from least a second, third, fourth or more formalin fixed biological samples. 2. Determining increased or decreased presence of the DR5 protein by comparing the SRM/MRM signature peak area from a given DR5 5 peptide detected in a Liquid TissueTM lysate from one formalin fixed biological sample to SRM/MRM signature peak areas developed from fragment peptides from other proteins, in other samples derived from different and separate biological sources, where the SRM/MRM signature peak area comparison between the 2 samples for a peptide 10 fragment are normalized to amount of protein analyzed in each sample. 3. Determining increased or decreased presence of the DR5 protein by comparing the SRM/MRM signature peak area for a given DR5 peptide to the SRM/MRM signature peak areas from other fragment 15 peptides derived from different proteins within the same Liquid TissueTM lysate from the formalin fixed biological sample in order to normalize changing levels of DR5 protein to levels of other proteins that do not change their levels of expression under various cellular conditions. 20 4. These assays can be applied to both unmodified fragment peptides and for modified fragment peptides of the DR5 protein, where the modifications include but are not limited to phosphorylation and/or glycosylation, and where the relative levels of modified peptides are determined in the same manner as determining relative amounts of 25 unmodified peptides. ii. Absolute quantitation of a given peptide may be achieved by comparing the SRM/MRM signature peak area for a given fragment peptide from the DR5 protein in an individual biological sample to the SRM/MRM signature peak area of an internal fragment peptide standard spiked into the protein lysate 30 from the biological sample. 1. The internal standard is a labeled synthetic version of the fragment peptide from the DR5 protein that is being interrogated. This standard is spiked into a sample in known amounts, and the SRM/MRM signature peak area can be determined for both the internal fragment 11 WO 2013/044261 PCT/US2012/056961 peptide standard and the native fragment peptide in the biological sample separately, followed by comparison of both peak areas. 2. This can be applied to unmodified fragment peptides and modified fragment peptides, where the modifications include but are not limited 5 to phosphorylation and/or glycosylation, and where the absolute levels of modified peptides can be determined in the same manner as determining absolute levels of unmodified peptides. III. Apply Fragment Peptide Quantitation to Cancer Diagnosis and Treatment a. Perform relative and/or absolute quantitation of fragment peptide levels of the DR5 10 protein and demonstrate that the previously-determined association, as well understood in the field of cancer, of DR5 protein expression to the stage/grade/status of cancer in patient tumor tissue is confirmed. b. Perform relative and/or absolute quantitation of fragment peptide levels of the DR5 protein individually, in combinations, or all simultaneously, and demonstrate 15 correlation with clinical outcomes from different treatment strategies, wherein this correlation has already been demonstrated in the field or can be demonstrated in the future through correlation studies across cohorts of patients and tissue from those patients. Once either previously established correlations or correlations derived in the future are confirmed by this assay then the assay method can be used to determine 20 optimal treatment strategy. The information shown in Table 2 is necessary to develop an SRM/MRM assay for quantitation of the DR5 protein on a triplequadrupole mass spectrometer. Specific and unique characteristics about these DR5 peptides were developed by analysis of all DR5 peptides on an ion trap and/or triple quadrupole mass spectrometers. That information includes the 25 monoisotopic mass of the peptide, its precursor charge state, the precursor m/z value, the transition m/z values of the precursor, and the ion types of each of the identified transitions. That information must be determined experimentally for each and every candidate SRM/MRM peptide directly in Liquid TissueTM lysates from formalin fixed tissue; because, interestingly, not all peptides from the DR5 protein can be detected in such lysates using SRM/MRM as described 30 herein, indicating that DR5 peptides not detected cannot be considered candidate peptides for developing an SRM/MRM assay for use in quantitating peptides/proteins directly in Liquid TissueTM lysates from formalin fixed tissue. Utilizing this information, quantitative SRM/MRM assays can be developed for the DR5 protein, and assessment of DR5 protein levels in tissues based on analysis of formalin fixed 12 WO 2013/044261 PCT/US2012/056961 patient-derived tumor tissue can provide diagnostic, prognostic, and therapeutically-relevant information about each particular cancer patient. In one embodiment, this disclosure provides methods for measuring the level of the DR5 protein in a biological sample, comprising detecting and/or quantifying the amount of one or 5 more modified or unmodified DR5 fragment peptides in a protein digest prepared from the biological sample using mass spectrometry; and calculating the level of modified or unmodified DR5 protein in the sample; and wherein the level is a relative level or an absolute level. In another embodiment, this disclosure provides a method for quantifying one or more DR5 fragment peptides, wherein the method comprises determining the amount of one or more of the 10 DR5 fragment peptides in a biological sample by comparison to an added internal standard peptide of known amount, wherein each of the DR5 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence. In some embodiments the internal standard is an isotopically labeled internal standard peptide comprising one or more heavy stable isotopes selected from 180, 17O, S, 15 N, 13 C, 2 H or combinations 15 thereof. The methods for measuring levels of the DR5 protein in a biological sample described herein (or fragment peptides as surrogates thereof) are useful as diagnostic indicators of cancer in a patient or subject. In one embodiment, the results from the measurements of levels of the DR5 protein may be employed to determine the diagnostic stage/grade/status of a cancer by correlating (e.g., 20 comparing) the level of DR5 protein found in a tissue with the level of these proteins found in normal and/or cancerous or precancerous tissues. 13 WO 2013/044261 PCT/US2012/056961 Embodiments: 1. A method for measuring the amount of the DR5 protein in a biological sample, comprising detecting and/or quantifying the level of one or more modified or unmodified DR5 fragment peptides in a protein digest prepared from the biological sample using mass 5 spectrometry; and calculating the level of modified or unmodified DR5 protein in the sample; and wherein the amount is a relative amount or an absolute amount. 2. The method of embodiment 0, further comprising the step of fractionating the protein digest prior to detecting and/or quantifying the level of one or more modified or unmodified DR5 10 fragment peptides. 3. The method of embodiment 2, wherein the fractionating step is selected from the group consisting of gel electrophoresis, liquid chromatography, capillary electrophoresis, nano reversed phase liquid chromatography, high performance liquid chromatography, and reverse phase high performance liquid chromatography. 15 4. The method of any of embodiments 1 to 3, wherein the protein digest of the biological sample is prepared by the Liquid TissueTM protocol. 5. The method of any of embodiments 1 to 3, wherein the protein digest comprises a protease digest. 6. The method of embodiment 5, wherein the protein digest comprises a trypsin digest. 20 7. The method of any of embodiments 1 to 6, wherein the mass spectrometry comprises tandem mass spectrometry, ion trap mass spectrometry, triple quadrupole mass spectrometry, MALDI-TOF mass spectrometry, MALDI mass spectrometry, or time of flight mass spectrometry, or any combination thereof. 8. The method of embodiment 7, wherein the mode of mass spectrometry used is Selected 25 Reaction Monitoring (SRM), Multiple Reaction Monitoring (MRM), or multiple Selected Reaction Monitoring (mSRM), or any combination thereof. 9. The method of any of embodiments 1 to 8, wherein the one or more modified or unmodified DR5 fragment peptides comprise different amino acid sequences independently selected from those set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. 30 10. The method of any of embodiments 0 to 9, wherein the biological sample is a blood sample, a urine sample, a serum sample, an ascites sample, a sputum sample, lymphatic fluid, a saliva sample, a cell, or a solid tissue. 14 WO 2013/044261 PCT/US2012/056961 11. The method of embodiment 10, wherein the tissue is formalin fixed tissue. 12. The method of embodiment 10 or 11, wherein the tissue is paraffin embedded tissue. 13. The method of embodiment 10, wherein the tissue is obtained from a tumor. 14. The method of embodiment 13, wherein the tumor is a primary tumor. 5 15. The method of embodiment 13, wherein the tumor is a secondary tumor. 16. The method of any of embodiments 0 to 15, further comprising quantifying a modified or unmodified DR5 fragment peptide. 17. The method of embodiment 16, wherein quantifying a modified or unmodified fragment peptide comprises comparing the amount of one or more DR5 fragment peptides comprising an 10 amino acid sequence of about 8 to about 45 amino acid residues of DR5 as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 in one biological sample to the amount of the same DR5 fragment peptide in a different and separate biological sample. 18. The method of embodiment 17, wherein quantifying one or more modified or unmodified DR5 fragment peptides comprises determining the amount of the each of said one or more DR5 15 fragment peptides in a biological sample by comparison to an added internal standard peptide of a known amount, wherein each of the DR5 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence. 19. The method of embodiment 18, wherein the internal standard peptide is an isotopically labeled peptide. 20 20. The method of embodiment 19, wherein the isotopically labeled internal standard peptide comprises one or more heavy stable isotopes selected from the group consisting of "0, 70, 3S, 15 N, 13 C, and 2 H, or any combinations thereof. 21. The method of any of embodiments 1 to 20, wherein detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides in the protein digest 25 indicates the presence of modified or unmodified DR5 protein and an association with cancer in the subject. 22. The method of embodiment 21, further comprising correlating the results of detecting and/or quantifying amounts of one or more modified or unmodified DR5 fragment peptides, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer. 30 23. The method of embodiment 22, wherein correlating the results of detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides, or the 15 WO 2013/044261 PCT/US2012/056961 amount of the DR5 protein to the diagnostic stage/grade/status of the cancer is combined with detected and/or quantified amounts of other proteins, or peptides from other proteins, in a multiplex format to provide additional information about the diagnostic stage/grade/status of the cancer. 5 24. The method of any one of embodiments 1 to 23, further comprising selecting for the subject, from which the biological sample is obtained, a treatment based on the presence, absence, or amount of one or more DR5 fragment peptides or the amount of DR5 protein. 25. The method of any one of embodiments 1 to 24, further comprising administering to the patient from which the biological sample is obtained a therapeutically effective amount of a 10 therapeutic agent, wherein the therapeutic agent and/or amount of the therapeutic agent administered is based upon the amount of one or more modified or unmodified DR5 fragment peptides or the amount of DR5 protein. 26. The method of embodiments 24 or 25, wherein the treatment or the therapeutic agent is directed to cancer cells expressing DR5 protein. 15 27. The method of any of embodiments 1 to 26, wherein the biological sample is formalin fixed tumor tissue that has been processed for quantifying the amount of one or more modified or unmodified DR5 fragment peptides employing the Liquid TissueTM protocol and reagents. 28. The method of any of embodiments 1-27, wherein said one or more modified or unmodified DR5 fragment peptides is one, two, or more of the peptides in Table 1. 20 29. The method of any of embodiments 1-28, comprising quantifying the amount of the peptides in Table 2. 30. A composition comprising one, two, or three of the peptides in Table 1 or antibodies thereto, said composition optionally excluding one, two, three or more peptides of DR5 that are not peptides of SEQ ID NOs: 1, 2, and /or 3. 25 31. The composition of embodiment 30, comprising two, or three of the peptides of Table 2 or antibodies thereto. It is to be understood that the description, specific examples, embodiments, and data, while indicating exemplary aspects, are given by way of illustration and are not intended to limit the resent disclosure. Various changes and modifications within the present disclosure will 30 become apparent to the skilled artisan from the discussion, detailed description, and data contained herein, and thus are considered part of the subject matter of this application.optionally excluding one, two, three or more peptides of DR5 that are not peptides of SEQ ID NOs: 1, 2, and /or 3. 16

Claims (31)

1. A method for measuring the amount of the DR5 protein in a biological sample, comprising detecting and/or quantifying the level of one or more modified or unmodified DR5 fragment peptides in a protein digest prepared from the biological sample using mass spectrometry; and calculating the level of modified or unmodified DR5 protein in the sample; and wherein the amount is a relative amount or an absolute amount.

2. The method of claim 0, further comprising the step of fractionating the protein digest prior to detecting and/or quantifying the level of one or more modified or unmodified DR5 fragment peptides.

3. The method of claim 2, wherein said fractionating step is selected from the group consisting of gel electrophoresis, liquid chromatography, capillary electrophoresis, nano reversed phase liquid chromatography, high performance liquid chromatography, and reverse phase high performance liquid chromatography.

4. The method of claim 1, wherein said protein digest of said biological sample is prepared by the Liquid TissueTM protocol.

5. The method of claim 1, wherein said protein digest comprises a protease digest.

6. The method of claim 5, wherein said protein digest comprises a trypsin digest.

7. The method of claim 1, wherein said mass spectrometry comprises tandem mass spectrometry, ion trap mass spectrometry, triple quadrupole mass spectrometry, MALDI-TOF mass spectrometry, MALDI mass spectrometry, or time of flight mass spectrometry, or any combination thereof.

8. The method of claim 7, wherein the mode of mass spectrometry used is Selected Reaction Monitoring (SRM), Multiple Reaction Monitoring (MRM), or multiple Selected Reaction Monitoring (mSRM), or any combination thereof.

9. The method of claim 1, wherein said one or more modified or unmodified DR5 fragment peptides comprise two or three different amino acid sequences independently selected from those set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

10. The method of claim 1, wherein said biological sample is a blood sample, a urine sample, a serum sample, an ascites sample, a sputum sample, lymphatic fluid, a saliva sample, a cell, or a solid tissue.

11. The method of claim 10, wherein said tissue is formalin fixed tissue. 17 WO 2013/044261 PCT/US2012/056961

12. The method of claim 10, wherein said tissue is paraffin embedded tissue.

13. The method of claim 10, wherein said tissue is obtained from a tumor.

14. The method of claim 13, wherein said tumor is a primary tumor.

15. The method of claim 13, wherein said tumor is a secondary tumor.

16. The method of claim 1, further comprising quantifying a modified or unmodified DR5 fragment peptide.

17. The method of claim 16, wherein quantifying a modified or unmodified fragment peptide comprises comparing the amount of one or more DR5 fragment peptides comprising an amino acid sequence of about 8 to about 45 amino acid residues of DR5 as shown in SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO:3 in one biological sample to the amount of the same DR5 fragment peptide in a different and separate biological sample.

18. The method of claim 17, wherein quantifying one or more modified or unmodified DR5 fragment peptides comprises determining the amount of the each of said DR5 fragment peptides in a biological sample by comparison to an added internal standard peptide of a known amount, wherein each of said DR5 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence.

19. The method of claim 18, wherein said internal standard peptide is an isotopically labeled peptide.

20. The method of claim 19, wherein said isotopically labeled internal standard peptide comprises one or more heavy stable isotopes selected from the group consisting of 180, 17o, 34s, 1N, 1C, and 2H, or any combinations thereof.

21. The method of claim 1, wherein detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides in said protein digest indicates the presence of modified or unmodified DR5 protein and an association with cancer in the subject.

22. The method of claim 21, further comprising correlating the results of detecting and/or quantifying amounts of one or more modified or unmodified DR5 fragment peptides, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer.

23. The method of claim 22, wherein correlating the results of detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer is combined with detected and/or quantified amounts of other proteins, or peptides from other proteins, in a multiplex format to provide additional information about the diagnostic stage/grade/status of the cancer. 18 WO 2013/044261 PCT/US2012/056961

24. The method of claim 1, further comprising selecting for the subject, from which the biological sample is obtained, a treatment based on the presence, absence, or amount of one or more DR5 fragment peptides or the amount of DR5 protein.

25. The method of claim 1, further comprising administering to the patient from which the biological sample is obtained a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent and/or amount of the therapeutic agent administered is based upon the amount of one or more modified or unmodified DR5 fragment peptides or the amount of DR5 protein.

26. The method of claim 24, wherein the treatment or the therapeutic agent is directed to cancer cells expressing DR5 protein.

27. The method of claim 1, wherein the biological sample is formalin fixed tumor tissue that has been processed for quantifying the amount of one or more modified or unmodified DR5 fragment peptides employing the Liquid TissueTM protocol and reagents.

28. The method of claim 1, wherein said one or more modified or unmodified DR5 fragment peptides is one, two, or more of the peptides in Table 1.

29. The method of claim 1, comprising quantifying the amount of one or more or two or more of the peptides in Table 2.

30. A composition comprising one, two, or more of the peptides in Table 1 or antibodies thereto.

31. The composition of claim 30 comprising two, or three of the peptides of Table 2 or antibodies thereto. 19 01152_8025_WO00_SEQ_LISTING_Sept_24_2012.TXT SEQUENCE LISTING <110> Expression Pathology Inc <120> MRM/SRM Assay for Death Receptor 5 Protein <130> 01552 DR5 <150> US 61/538,096 <151> 2011-09-22 <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 15 <212> PRT <213> Homo sapiens <400> 1 Leu Leu Val Pro Ala Asn Glu Gly Asp Pro Thr Glu Thr Leu Arg 1 5 10 15 <210> 2 <211> 10 <212> PRT <213> Homo sapiens <400> 2 Ile Glu Asp His Leu Leu Ser Ser Gly Lys 1 5 10 <210> 3 <211> 17 <212> PRT <213> Homo sapiens <400> 3 Asp Ala Ser Val His Thr Leu Leu Asp Ala Leu Glu Thr Leu Gly Glu 1 5 10 15 Arg Page 1